Sep 2026· Breast Cancer· Vol 33, pp. 1383 - 1393· 0 citations· 32 references
Medicine
TL;DR
Preliminary clinical observations suggest that PB-PBT without lumpectomy achieves results within specific criteria and that it could be an option for breast cancer treatment using radiation therapy alone.
Abstract
We report on our initial clinical experience with partial breast proton beam therapy (PB-PBT) without tumor resection as an alternative to partial mastectomy for low-risk early-stage breast cancer. This trial commenced in 2015, and eligibility criteria included women with cT1N0M0 invasive ductal carcinoma, estrogen receptor positivity, human epidermal growth factor receptor type-2 negativity, age of 40–70 years, and a performance status of 0 or 1. In Phase I, PB-PBT was administered at 62.4 Gy (RBE) in 26 fractions using the field-in-field technique. After confirming that no serious adverse events occurred, Phase II was conducted using the same dose. Follow-up evaluations were conducted every 3 months for the first year after irradiation and every 6 months thereafter. As of December 2025, 11 patients had completed a follow-up of ≥ 5 years. The median follow-up time was 82 months. Tumors exhibited immediate shrinkage post-PB-PBT, with morphological changes on ultrasonography and magnetic resonance imaging observed within 3–6 months. No recurrence was observed within the irradiated field in patients with > 5 years of follow-up. Dermatitis was Grade 1 in 55% of cases and Grade 2 in 45%; there were no cases of Grade ≥ 3. Grade 1 telangiectasia was observed in 36% of patients after 2 years, although most patients tolerated the treatment well. Preliminary clinical observations suggest that PB-PBT without lumpectomy achieves results within specific criteria and that it could be an option for breast cancer treatment using radiation therapy alone.
PBI using interstitial multi-catheter high dose-rate brachytherapy is effective and well-tolerated for selected early-stage breast cancer showing excellent long-term toxicity, cosmetic profiles, and outcomes.
Valeria Epifani, P. Anselmo, F. Arcidiacono et al.· Brachytherapy· 0 citations
Current evidence supports a more individualized approach to boost prescription based on recurrence risk, patient age, tumor biology, margin status, treatment techniques, and patient preference, and unresolved clinical issues still remain about the management of positive or close margins.
I. Benevento, A. Solazzo, F. Tortoreto et al.· Journal of Personalized Medi...· 0 citations
Findings support this approach for appropriately selected patients in routine clinical care for intermediate- and high-risk prostate cancer, as contemporary real-world evidence remains limited.
Z. El Kouzi, M. Rooney, Adam B. Samman et al.· Brachytherapy· 0 citations
PURPOSE
To report long-term oncologic, cosmetic, and toxicity outcomes of permanent breast seed implantation (PBSI) using palladium-103 as accelerated partial breast irradiation (APBI) for early-stage breast cancer.
METHODS AND MATERIALS
This prospective, single-institution study enrolled 27 patients in 2013-2015. Ou...
U. Amit, T. Meyer, M. Roumeliotis et al.· Brachytherapy· 0 citations
PURPOSE
To evaluate the efficacy and safety of carbon ion radiotherapy (CIRT) in patients with non-metastatic, inoperable pancreatic cancer in a prospective phase 2 setting.
METHODS
In this single-center investigator-initiated phase 2 trial, 25 patients with locally advanced or locally recurrent pancreatic cancer wer...
J. Liermann, P. Naumann, C. Jäkel et al.· Radiotherapy and Oncology· 0 citations
Introduction: Sentinel lymph node biopsy (SLNB) safety after neoadjuvant therapy in initially node-positive (cN+) breast cancer remains controversial. Additionally, evidence regarding the use of a single mapping tracer in this setting is limited.
Methods: Women with non-metastatic cT1–3 cN0–cN2 breast cancer who were...
M. B. Kraft, Arthur Chaves de Almeida, F. Brenelli et al.· Mastology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.